Dianthus | Affinity Screening
-
Read
Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust
-
[New] Dianthus with Spectral Shift
Learn how
Overcome your biggest challenges when characterizing PROTAC binary and ternary complexes. -
Read
Rely on Dianthus to overcome roadblocks in your PROTAC characterizations
-
ReadNanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
-
Read
Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus
-
2:30WatchDianthus: Tackle your most challenging affinity screenings with breakthrough Spectral Shift technology
-
Read
Going small to win big: Fragment-based screening in drug discovery
-
25:01WatchHow to find promising small molecule lead compounds with biophysical tools
Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.
-
Ready to tackle your challenging affinity screening?
Learn more
Discover tools you can use -
Read9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
-
Read10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
-
ReadTargeted protein degradation promises to lead the way to effective drugs for challenging targets
-
ReadHigh-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale
-
ReadWhy so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
-
35:47WatchImprove your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
ReadMST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
-
ReadFast Mek1 hit identification with TRIC technology correlates well with other biophysical methods
-
56:52WatchAdventures in drug discovery - The quest for your best small molecule
Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
-
59:35WatchHow to improve the function of your PROTAC degrader by understanding ternary complex formation
Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
-
Read
Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus
-
Read
How to build an effective protein degrader
-
ReadProtein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
Loading more...
